CGEM Cullinan Therapeutics, Inc.
Price Chart
Executive Summary
Cullinan Therapeutics released clinical data on two T cell engager programs (CLN-978 and velinotamig) for autoimmune diseases, showing early signs of efficacy including remissions in RA and SLE patients. The data are early-stage and from small patient numbers; no formal efficacy endpoint achieved, no approval decisions imminent. The press release is favorable but interim and not yet de-risking the pipeline at scale.
Actionable Insight
Early-stage data are encouraging but from very small sample sizes (2-3 patients per indication) — insufficient to change probability of success estimates materially. Traders should watch for the next multi-dose data readouts in RA (Q3 2026) and SLE (Q4 2026) for CLN-978, and for velinotamig data in Q4 2026 from the China trial, which will provide larger samples and better signal quality.
Key Facts
- CLN-978 data from first multi-dose RA cohort: one out of two patients achieved DAS28-ESR remission (score reduced from 4.0 at baseline to 2.2 at week 4, maintained through week 8)
- SLE safety data for first three multi-dose patients described as consistent with prior safety profile; proteinuria improvement supports planned lupus nephritis Phase 2a expansion in early 2027
- Velinotamig data from first two SLE patients: both achieved complete renal response; SLEDAI-2K scores dropped from 16 and 14 at baseline to 0 and 2 at week 8, respectively; no CRS or ICANS observed
- Additional multi-dose data expected for CLN-978 in RA in Q3 2026, SLE in Q4 2026; velinotamig data from Genrix Bio China trial expected in Q4 2026
- Cullinan plans to initiate Phase 1/2a for velinotamig in autoimmune cytopenias (ITP, AIHA) in Q1 2027
Financial Impact
No financial figures disclosed; $810M market cap implies modest near-term commercial value for early-stage programs
Risk Factors
- Small sample sizes (2-3 patients) mean results may not replicate in larger trials
- All data are interim and subject to change with longer follow-up and more patients
- Multiple planned trials require significant capital; dilution risk exists for $810M market cap company
- Competition exists from other CD19/B-cell targeting modalities (CAR-Ts, bispecifics) already in or closer to late-stage development for autoimmune diseases
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3309602 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
2d ago
|
Institutional Cluster
| $12.04 awaiting T+5 | awaiting T+5 | — | $13.70 (+13.79%) |
|
Jun 10, 2026
3d ago
|
Press Release
| $13.20 awaiting T+5 | awaiting T+5 | — | $13.70 (+3.79%) |
|
Jun 8, 2026
5d ago
|
8-K
| $13.51 awaiting T+5 | awaiting T+5 | — | $13.70 (+1.44%) |
|
May 19, 2026
25d ago
|
Press Release
| $14.18 $15.52 | ▲ +9.49% | ▲ +7.19% | $13.70 (−3.35%) |
|
May 18, 2026
25d ago
|
8-K
| $14.18 $15.52 | ▲ +9.49% | ▲ +7.19% | $13.70 (−3.35%) |
|
May 18, 2026
25d ago
|
Press Release
| $14.18 $15.52 | ▲ +9.49% | ▲ +7.19% | $13.70 (−3.35%) |
|
Mar 10, 2026
13w ago
|
Press Release
| $14.91 $13.44 | ▼ −9.86% | ▼ −8.95% | $13.70 (−8.12%) |
|
Feb 24, 2026
15w ago
|
Insider Cluster
| $14.27 $15.73 | ▼ −10.23% | ▼ −11.26% | $13.70 (+3.99%) |
|
Feb 24, 2026
15w ago
|
Insider Cluster
| $14.27 $15.73 | ▼ −10.23% | ▼ −11.26% | $13.70 (+3.99%) |
|
Feb 24, 2026
15w ago
|
Insider Cluster
| $14.27 $15.73 | ▼ −10.23% | ▼ −11.26% | $13.70 (+3.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access